- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03373071
Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
Phase I/II Study of Anti-CD19 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma
Study Overview
Status
Intervention / Treatment
Detailed Description
The study will consist of 2 phases, a Phase I or dose escalation phase and a Phase II or expansion phase. Paediatric/young adult patients with relapsed or refractory B cell ALL will be enrolled. Eligible patients will undergo leukapheresis in order to harvest T cells, which is the starting material for the manufacture. Autologous CAR T product directed against CD19-expressing tumor cells (CD19-CART01) will be produced and, after a lymphodepletion with conventional chemoterapic agents, the patient will receive CD19-CART01 intravenously. The construct contains also the suicide gene safety switch "inducible Caspase 9"; therefore, in case of relevant toxicities, the patient will receive the dimerizing agent in order to induce the apoptosis of the cells.
After the treatment, the patients will then enter a 36-month follow-up period.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Roma, Italy
- Ospedale Pediatrico Bambino Gesù
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male and female subjects with CD19 expressing B-cell acute lymphoblastic leukemia (ALL) or Non-Hodgkin Lymphoma (NHL) with BM involvement and one of the following:
i. Patients in 2nd or subsequent relapse, after at least one standard frontline chemotherapy and one salvage regimen, with BM involvement ii. Relapse after allogeneic HSCT, if at least 100 days post-transplant, if there is no evidence of active GVHD and if the patient is no longer taking immunosuppressive agents for at least 30 days prior to enrollment iii. MRD > 0.1% after either reinduction therapy or any course of consolidation for relapsed ALL
- Measurable or evaluable disease at the time of enrollment, which may include any evidence of disease, including MRD detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.
- Age: 6 months - 25 years.
- Voluntary informed consent is given. For subjects < 18 year-old their legal guardian must give informed consent. Pediatric subjects will be included in age-appropriate discussion and verbal assent will be obtained for those greater than or equal to 12 years of age, when appropriate.
- Clinical performance status: Patients > 16 years of age: Karnofsky greater than or equal to 60%; Patients < 16 years of age: Lansky scale greater than or equal to 60%.
- Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen.
- Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.
Exclusion Criteria:
- Pregnant or lactating women
- Severe, uncontrolled active intercurrent infections
- HIV, or active HCV and/or HBV infection
- Life-expectancy < 6 weeks
- Hepatic function: Inadequate liver function defined as total bilirubin > 4x upper limit of normal (ULN) or transaminase (ALT and AST) > 6 x ULN
- Renal function: serum creatinine > 3x ULN for age.
- Blood oxygen saturation < 90%.
- Cardiac function: Left ventricular ejection fraction lower than 45% by ECHO.
- Congestive heart failure, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject.
- BM blasts > 50% pre-infusion.
- Hyperleukocytosis (greater than or equal to 20,000 blasts/microliter) or rapidly progressive disease that in the evaluation of the investigator would compromise ability to complete study therapy
- Active CNS disease as documented by the presence of blasts in the CSF or by MRI. This criterion could be revised once that, after the phase I portion of the study, absence of life-threatening (i.e. grade IV) neurological toxicity will be documented.
- Presence of active, grade 2-4 acute or extensive chronic GvHD
- Recurrent or refractory ALL with testicular involvement
Concurrent or recent prior therapies, before infusion:
i. Systemic steroids (at a dose > 2 mg/kg prednisone) in the 2 weeks before infusion. Recent or current use of inhaled/topical/non-absorbable steroids is not exclusionary.
ii. Systemic chemotherapy in the 2 weeks preceding infusion. iii. Anti-thymocyte globulin (ATG) or Alemtuzumab (Campath®) in the 4 weeks preceding infusion.
iv. Immunosuppressive agents in the 2 weeks preceding infusion. v. Radiation therapy must have been completed at least 3 weeks prior to enrollment.
vi. Other anti-neoplastic investigational agents currently administered or within 30 days prior to infusion (i.e. start of protocol therapy);
vii. Exceptions:
- There is no time restriction with respect to prior intrathecal chemotherapy, provided that there is complete recovery from any acute toxic effects of such;
- Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study provided that they meet all other eligibility criteria;
- Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided that there has been no increase in dose for at least 2 weeks prior to starting apheresis;
- Patient-derived CD19-CART01 production failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CD19-CART01
Following the lymphodepleting treatment, with patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose
|
Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose. In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I - Identification of the dose limiting toxicity (DLT)
Time Frame: 4 weeks after CAR T cell infusion
|
Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) scale, version 4 and the number of patients experiencing DLT will be evaluated
|
4 weeks after CAR T cell infusion
|
Phase II - Efficacy
Time Frame: 4 weeks after CAR T cell infusion
|
Complete remission rate minimal residual disease (MRD) negative response
|
4 weeks after CAR T cell infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: 4 weeks after CAR T cell infusion
|
Assessment of CR with incomplete blood count recovery (CRi), Partial Response (PR) and Stable Disease (SD).
|
4 weeks after CAR T cell infusion
|
In vivo persistence/expansion of infused CAR T cell
Time Frame: Up to 5 years
|
Detection of infused CAR T cell in the peripheral and bone marrow blood
|
Up to 5 years
|
Function of infused CAR T cell
Time Frame: Up to 5 years
|
Assessment through functional assays (such as ELISPOT for interferon-gamma release using CD19-positive cells and CD19-negative target cells) and immunophenotyping on peripheral blood mononuclear cells (PBMCs) isolated from the patients
|
Up to 5 years
|
Cytokine profiling
Time Frame: 10 days after CAR T cell infusion
|
Define serum cytokine profile after T cell infusion and correlation with cytokine release syndrome (CRS)
|
10 days after CAR T cell infusion
|
Disease Outcome
Time Frame: Up to 3 years
|
Assessment of relapse rate
|
Up to 3 years
|
Overall Survival
Time Frame: Up to 3 years
|
Up to 3 years
|
|
Disease-free survival
Time Frame: Up to 3 years
|
Up to 3 years
|
|
Elimination of CAR T cell in case of toxicity
Time Frame: Up to 15 years
|
Assessment the kinetics of CAR T cells elimination after AP1903 infusion
|
Up to 15 years
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CD19-CAR01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CD19-ALL
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalNot yet recruitingCD19-positive Relapsed or Refractory B-cell MalignanciesChina
-
The Second Affiliated Hospital of Henan University...First Affiliated Hospital of Wenzhou Medical University; Second Affiliated... and other collaboratorsUnknown
-
University College, LondonCompletedCD19+ Malignancies: Relapse Post-allogeneic TransplantUnited Kingdom
-
First Affiliated Hospital Xi'an Jiaotong UniversityEureka Therapeutics Inc.UnknownCD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-CellChina
-
Seattle Children's HospitalActive, not recruitingCD19+ Acute LeukemiaUnited States
-
Precision BioSciences, Inc.RecruitingHematologic Malignancy | CD19 Expressing MalignanciesUnited States
-
Shenzhen Geno-Immune Medical InstituteThe Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaboratorsRecruiting
-
Chinese PLA General HospitalRecruitingCD19+ Relapse/Refractory B-ALLChina
-
PETHEMA FoundationTerminatedPhiladelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALLSpain
-
The Christie NHS Foundation TrustTerminatedCD19 Positive Non-Hodgkin LymphomaUnited Kingdom
Clinical Trials on CD19-CAR T cell
-
Wuhan Union Hospital, ChinaGuangzhou Bio-gene Technology Co., LtdNot yet recruitingSystemic Lupus Erythematosus
-
The Affiliated Hospital of Qingdao UniversityNot yet recruitingDiffuse Large B Cell Lymphoma
-
University of Colorado, DenverRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoid LeukemiaUnited States
-
Hebei Yanda Ludaopei HospitalGracell Biotechnology Ltd.UnknownMultiple MyelomaChina
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingLymphoma | Multiple Myeloma | Acute Lymphoblastic LeukemiaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina
-
920th Hospital of Joint Logistics Support Force...RecruitingB-Cell Leukemia | B-Cell Lymphoma | B-cell TumorsChina
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityNanjing Legend Biotech Co.Terminated
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityNanjing Legend Biotech Co.WithdrawnRefractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic LeukemiaChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalRecruiting